Researchers tackle racial/ethnic disparities in HIV medical studies

July 7, 2014
Researchers tackle racial/ethnic disparities in HIV medical studies

A New York University College of Nursing (NYUCN) research team found that a social/behavioral intervention vastly increased the number of African American and Latino individuals living with HIV/AIDS who enrolled in HIV/AIDS medical studies. The intervention, designed by researchers at the NYUCN's Center for Drug Use and HIV Research (CDUHR), found that nine out of ten participants who were found eligible for studies decided to enroll, compared to zero participants among a control group.

The study, called "ACT2," addresses a long-recognized problem: the racial/ethnic groups most affected by HIV are chronically under-represented in HIV/AIDS medical research. While 50% of all people living with HIV/AIDS are African American/Black, they comprise a mere 30% of those enrolled in HIV/AIDS . Likewise, Latinos are also under-represented in such studies in many settings. This lack of proportional representation raises a number of questions, including about the applicability of medical research findings to the groups most affected by HIV/AIDS.

"The issue of under-representation of these racial/ethnic groups is well known, but it's a complex problem and not that easy to change," said Marya Gwadz, PhD, a senior research scientist at NYUCN and lead author of the study. "Our study is the first to have tested social/behavioral intervention strategies to reduce barriers to HIV medical studies for these under-represented populations."

The ACT2 study demonstrated a thirty-fold increase in rates of screening for HIV/AIDS medical studies among African Americans and Latinos living with HIV/AIDS compared to a control group. As reported in the June 2014 issue of AIDS and Behavior, half of those screened were found eligible for a study, and among those found eligible, 90% enrolled in at least one HIV/AIDS medical study. Among participants in the control group, screening was rare and, as a result, none in the control group enrolled.

"There are misconceptions that African Americans and Latinos are not interested in HIV/AIDS medical studies," said Dr. Gwadz. "We found that members of these groups are typically fearful of medical studies and also have socioeconomic barriers to accessing them. Yet we found that in the context of the ACT2 intervention program, which allows participants to learn more about trials, articulate these fears, and gain access to trials, they are very willing to explore the possibility of participating, and if they are found eligible and the study is right for them, also eager to enroll."

The ACT2 intervention uses a potent peer-driven recruitment and peer education intervention approach, combined with brief, structured small group and individual sessions delivered by trained counselors. The sessions focused on increasing awareness about the problem of disproportionate representation of people of color in HIV/AIDS medical studies, while also allowing participants to voice fears about these studies. Fear of medical studies is common among African American and Latino populations, and is rooted in the long-standing mistreatment of people of color in U.S. medical research. Participants in the control arm received a time-matched, small-group health education program.

The researchers focused on enrollment into both therapeutic/treatment clinical trials and biomedical observational studies, which have similar rates of racial/ethnic under-representation. They found that participants were much less likely to be found eligible for trials testing new treatments or therapies for HIV/AIDS, compared to observational studies that do not involve testing new treatments.

"While social/behavioral interventions such as ACT2 are important for increasing motivation and knowledge of medical studies, and providing support to navigate the complexity of screening and enrollment into studies among this population, we believe achieving appropriate racial/ethnic representation will require modification of study inclusion criteria to increase the proportion found eligible for therapeutic studies," noted Noelle Leonard, PhD, a co-investigator of the study at CDUHR.

Both the intervention and control groups were notified about the thirty ongoing HIV/AIDS medical studies in the New York City area where the study was conducted and were presented with the option to initiate screening to determine their eligibility. As part of the intervention, participants in the ACT2 intervention group were offered help in navigating the structural and personal barriers they might encounter to completing the often-complex screening process, while those in the were not offered navigation.

ACT2 draws its success by incorporating both the Theory of Normative Regulation—which posits that behaviors of individuals are amplified through their social groups—and Motivational Interviewing, a health behavior change method for fostering individuals' intrinsic motivation to make positive changes without applying pressure or judgment.

"Our participants have told us they want to contribute to their communities through research and help those with HIV who come after them," said Dr. Gwadz. "Yet the impediments they typically experience to participating in medical studies deny them this opportunity. ACT2 helps build a bridge between HIV/AIDS medical studies and communities of color."

Of the thirty medical studies available during the study period, twenty-three (76.6%) were therapeutic studies and seven (23.4%) were observational studies. Yet despite the vast majority of the studies being therapeutic, only 4% of ACT2 participants screened were eligible for such studies. Instead, the majority of (84.4%) were found eligible for observational studies.

"It is imperative that scientists who develop HIV/AIDS medical studies consider the implications of highly restrictive inclusion criteria and other design features on the participation of under-represented groups, while at the same time maintaining study validity," said Dr. Leonard.

The ACT2 intervention is designed to be administered by Master's level clinicians, and is comprised of six hours of staff-guided intervention sessions, and individualized navigation during the screening process, as needed. Participants also have the opportunity to independently educate their peers about medical studies, which is in itself a form of intervention. "ACT2 does not require a great deal of staff time to implement," said Dr. Gwadz, "but can potentially make a big difference in rates of enrollment among racial/ethnic minorities." ACT2 is one of the programs in the Substance Use and Mental Health Services Administration's (SAMHSA) National Registry of Evidence-based Programs and Practices.

Explore further: Conspiracy theories not to blame for underrepresentation in HIV studies

Related Stories

Conspiracy theories not to blame for underrepresentation in HIV studies

August 28, 2013
Even though most Americans believe some kind of conspiracy theory about HIV care and research, many are willing to take part in vaccine trails, according to a new study by Ryan Westergaard of the University of Wisconsin School ...

Many ER patients test positive for HIV while in most infectious stage

June 23, 2014
Human Immunodeficiency Virus (HIV) screening for emergency patients at an institution with a large number of ethnic minority, underinsured and uninsured people reveals few are HIV positive, but of those who are, nearly one-quarter ...

Aging with HIV and AIDS: A growing social issue

June 25, 2014
As the first people with HIV grow old, a new study from St. Michael's Hospital questions whether the health care system and other government policies are prepared to meet their complex medical and social needs.

Community-based HIV prevention can boost testing, help reduce new infections

April 15, 2014
(Medical Xpress)—Communities in Africa and Thailand that worked together on HIV-prevention efforts saw not only a rise in HIV screening but a drop in new infections, according to a new study in the peer-reviewed journal ...

Cutting HIV in drug users can benefit others' AIDS mortality

March 26, 2014
(HealthDay)—Efforts to curb HIV transmission among people who inject drugs (PWID) and non-injecting drug users (NIDUs) may reduce AIDS and AIDS-related mortality among heterosexuals, according to a study published in the ...

Uganda's president urged to veto 'flawed' HIV law

May 14, 2014
Rights groups are urging Uganda's president to veto a new measure that they say hurts the fight against HIV and AIDS in the country.

Recommended for you

Scientists divulge latest in HIV prevention

July 25, 2017
A far cry from the 1990s "ABC" campaign promoting abstinence and monogamy as HIV protection, scientists reported on new approaches Tuesday allowing people to have all the safe sex they want.

Girl's HIV infection seems under control without AIDS drugs

July 24, 2017
A South African girl born with the AIDS virus has kept her infection suppressed for more than eight years after stopping anti-HIV medicines—more evidence that early treatment can occasionally cause a long remission that, ...

Meds by monthly injection might revolutionize HIV care (Update)

July 24, 2017
Getting a shot of medication to control HIV every month or two instead of having to take pills every day could transform the way the virus is kept at bay.

Candidate AIDS vaccine passes early test

July 24, 2017
The three-decade-old quest for an AIDS vaccine received a shot of hope Monday when developers announced that a prototype triggered the immune system in an early phase of human trials.

Paris spotlight on latest in AIDS science

July 21, 2017
Some 6,000 HIV experts gather in Paris from Sunday to report advances in AIDS science as fading hopes of finding a cure push research into new fields.

Scientists elicit broadly neutralizing antibodies to HIV in calves

July 20, 2017
Scientists supported by the National Institutes of Health have achieved a significant step forward, eliciting broadly neutralizing antibodies (bNAbs) to HIV by immunizing calves. The findings offer insights for HIV vaccine ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.